{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:36:01Z","timestamp":1787114161680,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2025.12.011","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:14:15Z","timestamp":1769688855000},"page":"893-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safeguarding Cannabis for Medical Use: Clinical Risks, Regulatory Gaps, and the Path Toward Equitable Standards"],"prefix":"10.1016","volume":"48","author":[{"given":"Shawn P.","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.12.011_bib0001","unstructured":"National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids. WA, DC; 2017."},{"issue":"1","key":"10.1016\/j.clinthera.2025.12.011_bib0002","first-page":"79","article-title":"Cannabis and cannabinoid pharmacology: risk considerations","volume":"69","author":"Russo","year":"2017","journal-title":"Pharmacol Rev"},{"issue":"23","key":"10.1016\/j.clinthera.2025.12.011_bib0003","first-page":"2195","article-title":"Clinical considerations for cannabis as medicine","volume":"386","author":"Hurd","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clinthera.2025.12.011_bib0004","first-page":"187","article-title":"Cannabis use among patients with cancer and implications for safety","volume":"9","author":"Volkow","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0005","unstructured":"US Food and Drug Administration. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). Silver spring, MD: US food and drug administration; updated 2024. Accessed December 5, 2025. https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0006","series-title":"Federal marijuana law and policy: overview","year":"2024"},{"issue":"7","key":"10.1016\/j.clinthera.2025.12.011_bib0050","first-page":"547","article-title":"Pediatric exposures to marijuana: contamination concerns","volume":"54","author":"Wang","year":"2016","journal-title":"Clin Toxicol"},{"issue":"2","key":"10.1016\/j.clinthera.2025.12.011_bib0007","first-page":"135","article-title":"Early evidence of cannabis legalization on health outcomes","volume":"76","author":"Smart","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0008","series-title":"National Conference of State Legislatures. State medical cannabis testing laws. WA, DC","year":"2024"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0009","series-title":"Memorandum for all United States attorneys: guidance regarding marijuana enforcement","year":"2013"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0010","series-title":"Memorandum for all United States attorneys: marijuana enforcement","year":"2018"},{"issue":"2","key":"10.1016\/j.clinthera.2025.12.011_bib0051","first-page":"130","article-title":"Application of machine learning in cannabis quality assurance","volume":"7","author":"Cortes","year":"2023","journal-title":"AI Health"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0011","unstructured":"Health Canada. Guidance on Cannabis Testing and Quality Requirements. Ottawa, ON; 2024."},{"issue":"3","key":"10.1016\/j.clinthera.2025.12.011_bib0012","first-page":"447","article-title":"Cannabis contaminants in Europe: pesticides, metals, and solvents","volume":"12","author":"Hakkinen","year":"2020","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0013","unstructured":"International Council for Harmonisation (ICH). Q3D guideline for elemental impurities. Geneva, Switzerland; 2019."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0014","unstructured":"World Health Organization. Guidelines for quality control of herbal medicines. Geneva, Switzerland; 2018."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0015","unstructured":"American Herbal Pharmacopoeia. Cannabis inflorescence monograph. Scotts Valley, CA; 2013."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0016","unstructured":"United States Pharmacopeia. USP Cannabis Draft Monograph. Rockville, MD; 2023."},{"issue":"2","key":"10.1016\/j.clinthera.2025.12.011_bib0017","first-page":"44","article-title":"Yeast and mold thresholds in cannabis: challenges in state variability","volume":"10","author":"Craft","year":"2022","journal-title":"J Regul Sci"},{"issue":"7","key":"10.1016\/j.clinthera.2025.12.011_bib0018","first-page":"697","article-title":"Invasive aspergillosis in marijuana users with hematologic malignancy","volume":"55","author":"Thompson","year":"2017","journal-title":"Med Mycol"},{"issue":"6","key":"10.1016\/j.clinthera.2025.12.011_bib0019","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3201\/eid2606.191570","article-title":"Cannabis use and fungal infections in a commercially insured popul\u0100","volume":"26","author":"Benedict","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.clinthera.2025.12.011_bib0020","first-page":"1365","article-title":"Fungal contamination of herbal cannabis in Europe: implications for immunocompromised patients","volume":"25","author":"Klein","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0021","first-page":"45","article-title":"Case report: fatal pulmonary aspergillosis associated with medical cannabis","volume":"12","author":"Okhovat","year":"2018","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0022","series-title":"Administrative Order No. 4: Independent Testing Laboratories","year":"2025"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0023","series-title":"Administrative Order No. 5: Certificates of Analysis in METRC","year":"2025"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0024","series-title":"Suspension of Assured Testing Laboratories","year":"2025"},{"issue":"5","key":"10.1016\/j.clinthera.2025.12.011_bib0025","first-page":"1507","article-title":"Diversion and falsification in cannabis testing","volume":"66","author":"Hilderbrand","year":"2021","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0026","series-title":"Marijuana Enforcement Division. Marijuana recall and health\/safety advisory notices","author":"Colorado Department of Revenue","year":"2022"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0027","series-title":"Enforcement actions: laboratory license actions","author":"Nevada Cannabis Compliance","year":"2023"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0028","unstructured":"Michigan Department of Licensing and Regulatory Affairs. Marijuana Regulatory Agency: enforcement actions and related litigation summaries. Lansing, MI; 2021-2025."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0029","unstructured":"A2LA. Proficiency Testing for Cannabis Labs. A2LA website. Accessed December 15, 2025. https:\/\/a2la.org\/proficiency-testing-for-cannabis-labs\/3."},{"issue":"2","key":"10.1016\/j.clinthera.2025.12.011_bib0030","first-page":"316","article-title":"Cannabis analysis: advances in chromatography and spectroscopy","volume":"101","author":"Fischedick","year":"2018","journal-title":"J AOAC Int"},{"issue":"1","key":"10.1016\/j.clinthera.2025.12.011_bib0031","first-page":"22","article-title":"Adoption of qPCR in cannabis microbial testing","volume":"3","author":"Hudalla","year":"2021","journal-title":"J Cannabis Sci"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0032","first-page":"491","article-title":"Next-generation sequencing for cannabis microbial analysis","volume":"11","author":"McKernan","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0033","unstructured":"ACLU. A tale of two countries: racially targeted arrests in the era of cannabis reform. New York, NY; 2020."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0034","first-page":"245","article-title":"Cost barriers to medical cannabis adherence","volume":"16","author":"Caplan","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0035","article-title":"Fungal contaminants of cannabis: species diversity and impact","volume":"14","author":"Punja","year":"2023","journal-title":"Front Microbiol"},{"issue":"7","key":"10.1016\/j.clinthera.2025.12.011_bib0036","first-page":"455","article-title":"Mycotoxin risk in cannabis products: a systematic review","volume":"15","author":"Gwinn","year":"2023","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0037","unstructured":"Medicinal Genomics. Limitations of culture-based testing for cannabis safety. White Paper. 2023."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0038","article-title":"Cannabinoid interactions with antiepileptic drugs: clinical implications","volume":"136","author":"Sulak","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"11","key":"10.1016\/j.clinthera.2025.12.011_bib0039","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.clinthera.2025.12.011_bib0040","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"59","author":"Gaston","year":"2018","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.clinthera.2025.12.011_bib0041","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/jcm8070989","article-title":"Potential adverse drug events and drug\u2013drug interactions with medical and consumer cannabidiol use","volume":"8","author":"Brown","year":"2019","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.clinthera.2025.12.011_bib0042","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2131\/jts.40.797","article-title":"Understanding dabs: contamination concerns of cannabis concentrates","volume":"40","author":"Raber","year":"2015","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0043","unstructured":"Canadian Ministry of Veterans Affairs. Cannabis for medical purposes: coverage policy. Ottawa, ON; 2023."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0044","unstructured":"European Medicines Agency. Draft monograph on Cannabis flos. London, UK; 2025."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0045","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Medical cannabis regulation and reimbursement standards. Bonn, Germany; 2024."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0046","unstructured":"Israel Ministry of Health. Medical cannabis quality requirements and distribution model. Jerusalem, Israel; 2024."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0047","unstructured":"Therapeutic goods administration (TGA). quality guidance for medicinal cannabis products. Canberra, Australia; 2023."},{"key":"10.1016\/j.clinthera.2025.12.011_bib0048","article-title":"Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: rescheduling of marijuana","volume":"89","year":"2024","journal-title":"Federal Register"},{"key":"10.1016\/j.clinthera.2025.12.011_bib0049","unstructured":"Agriculture Improvement Act of 2018. 7 USC \u00a7 1639o (definitions). Accessed December 15, 2025. https:\/\/uscode.house.gov"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:33:54Z","timestamp":1787070834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825004217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0149291825004217"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safeguarding Cannabis for Medical Use: Clinical Risks, Regulatory Gaps, and the Path Toward Equitable Standards","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}